Our group focuses on the role of intestinal microbiota in chronic inflammation and human cardiometabolism in a translational fashion. We aim to find novel pathophysiological pathways driving cardiovascular disease, dyslipidemia and diabetes mellitus studying the role of baceria in adipose tissue, liver (NASH) and macrovascular inflammation. In line, we will try to identify novel therapeutic targets via identifying bacterial ligands or developing novel probiotic bacterial strains and vaccination leads to treat these diseases.
Effective start/end date01/12/2012 → …

ID: 179878